Fig. 3
From: The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer
Practice variation (physician level) for high volume mHSPC. All patient cases were ECOG 0, without comorbidities, symptoms and contra-indications for treatment strategies.Case 4 70 year old patient with newly diagnosed M1b prostate carcinoma, 5 bone metastases within the axial skeleton and 1 in the peripheral skeleton, high volume (per CHAARTED); Case 5 70 year old patient with newly diagnosed M1c prostate carcinoma, 5 bone metastases and 1 liver metastasis, high volume (per CHAARTED). Source: survey. Number of respondents: 23 urologists, 16 oncologists. mHSPC metastatic hormone-sensitive prostate cancer, ADT androgen deprivation therapy, RTx radiotherapy to the prostate, MDT metastasis directed therapy, Doc docetaxel, Apa apalutamide, Abi abiraterone, Enza enzalutamide, ECOG Eastern cooperative oncology group performance scale.
